Joseph Beckwith

Assistant Professor

University of Warwick
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

The non‐covalent interactions that underpin major cellular functions depend on molecular motion within 3D environments. Large depth‐of‐field single‐molecule localization microscopy (3D‐SMLM) methods facilitate these measurements, but their increased optical complexity and bespoke post‐processing pipelines often sacrifice important cellular context. Here, we combine single‐molecule light‐field microscopy (SMLFM) with widefield Fourier light‐field microscopy for correlative volumetric organelle imaging. The instantaneous acquisition of subcellular volumes improves the sensitivity of molecular organization, chemical environment, and diffusion measurements through the use of volumetric sub‐cellular segmentation. We first demonstrate our approach by measuring the molecular organization of a nuclear‐localized HaloTag protein relative to cell nuclei. Next, we characterize the molecular diffusion of the soluble protein, calreticulin, in the context of ‐antitrypsin deficiency, which revealed an increase in heterogeneous motion within endoplasmic reticulum inclusions.

Year:

2026

Parkinson’s disease (PD) is a neurodegenerative condition characterized by the presence of intraneuronal aggregates containing fibrillar ɑ-synuclein known as Lewy bodies. These large end-stage species are formed by smaller soluble protein nanoscale assemblies, often termed oligomers, which are proposed as early drivers of pathogenesis. Until now, this hypothesis has remained controversial, at least in part because it has not been possible to directly visualize nanoscale assemblies in human brain tissue. Here we present Advanced Sensing of Aggregates—Parkinson’s Disease, an imaging method to generate large-scale α-synuclein aggregate maps in post-mortem human brain tissue. We combined autofluorescence suppression with single-molecule fluorescence microscopy, which together enable the detection of nanoscale α-synuclein aggregates. To demonstrate the use of this platform, we analysed ~1.2 million nanoscale aggregates from the anterior cingulate cortex in human post-mortem brain samples from patients with PD and healthy controls. Our data reveal a disease-specific shift in a subpopulation of nanoscale assemblies that represent an early feature of the proteinopathy that underlies PD. We anticipate that quantitative information about this distribution provided by Advanced Sensing of Aggregates—Parkinson’s Disease will enable mechanistic studies to reveal the pathological processes caused by α-synuclein aggregation.

Year:

2025

Early cellular events in Parkinson’s disease (PD) remain elusive. While aggregation of α-synuclein (αSyn) into Lewy bodies marks advanced pathology, smaller αSyn oligomers have been implicated in prodromal stages. Here we map αSyn oligomers at single-particle resolution in post-mortem brain tissue from Braak stage 3/4 PD cases and matched controls. Quantitative imaging of 9,882 neurons across four regions captured over 112 million αSyn oligomers. Mean intracellular α-Syn burden was unchanged between groups, but PD samples contained a higher fraction of neurons whose oligomer load exceeded a specific aggregation threshold. We term these aggregation-susceptible cells (ASCs). ASC enrichment in vulnerable regions supports a population-level model in which early pathology arises from a stochastic shift in cellular composition rather than altered αSyn aggregation kinetics. This human-tissue, large-scale dataset provides a quantitative framework for detecting ASCs and for testing population-level interventions in PD and related proteinopathies.

Year:

2025

Protein aggregates are a pathological hallmark across neurodegenerative diseases. Yet, the disconnect between molecular-level aggregation and the emergence of disease severely limits mechanistic understanding of neurodegeneration. Here, we bridge this disconnect by showing that a cellular tipping point emerges as a universal feature across diseases from the competition between aggregate accumulation and removal. We map the resulting cellular phase transition with our high-throughput live-cell assay, measuring the tipping point that separates healthy cells from those with large aggregate loads. Using super-resolution imaging of brain tissue from Alzheimer’s and Parkinson’s disease, we quantify how the balance of accumulation and removal is shifted in disease. We validate our framework by predicting how designed aggregation inhibitors shift the tipping point to restore cellular homeostasis. Our results provide a mechanistic framework connecting molecular-level aggregation to disease, paving the way for a quantitative, unified understanding of neurodegeneration and enabling predictions of therapeutic efficacy.

Year:

2025

Parkinson’s disease (PD) is characterised by insoluble α-synuclein (αSyn) aggregates in Lewy bodies (LBs) within the substantia nigra, with cortical pathology appearing as the disease progresses. Late-stage LB deposition, cellular stress, and neuronal loss obscure disease-driving events, we therefore performed multi-regional transcriptomic and aggregate profiling in early-midstage PD brains (Braak 3–4), where cortical regions are pathologically unaffected. We report neuroimmune activation as an early PD feature, characterised by the expansion of a high- SNCA -expressing microglial state. This robust immune signature occurs prior to LB formation, but is associated with oligomeric αSyn within cortical microglia. In hiPSC-derived microglia, both endogenous αSyn oligomerisation, and exogenous oligomer uptake, trigger transcriptional reprogramming, characterised by interferon-driven inflammation, antigen presentation, and mitochondrial suppression, closely mirroring the early PD brain. These findings describe mechanisms by which αSyn oligomerisation potently initiates early neuroinflammation, highlighting a critical interplay between proteinopathy and immune activation at the earliest stages of disease.

Year:

2025

Early cellular events in Parkinson’s disease (PD) remain elusive. While aggregation of α-synuclein (αSyn) into Lewy bodies marks advanced pathology, smaller αSyn oligomers have been implicated in prodromal stages. Here we map αSyn oligomers at single-particle resolution in post-mortem brain tissue from Braak stage 3/4 PD cases and matched controls. Quantitative imaging of 9,882 neurons across four regions captured over 112 million αSyn oligomers. Mean intracellular α-Syn burden was unchanged between groups, but PD samples contained a higher fraction of neurons whose oligomer load exceeded a specific aggregation threshold. We term these aggregation-susceptible cells (ASCs). ASC enrichment in vulnerable regions supports a population-level model in which early pathology arises from a stochastic shift in cellular composition rather than altered αSyn aggregation kinetics. This human-tissue, large-scale dataset provides a quantitative framework for detecting ASCs and for testing population-level interventions in PD and related proteinopathies.

Year:

2025

The molecular interactions that underpin all cellular functions depend on molecular motion within three-dimensional environments. Large depth-of-field single-molecule localization microscopy (3D-SMLM) methods facilitate these measurements, but their increased optical complexity and bespoke post-processing pipelines can sacrifice important cellular context. Here we combine single-molecule light-field microscopy (SMLFM) with widefield Fourier light-field microscopy for correlative volumetric organelle imaging. The instantaneous acquisition of subcellular volumes improves the sensitivity of molecular organization and diffusion measurements through the rejection of non-specific localizations. We first demonstrate our approach by measuring the molecular organization of a nuclear-localized HaloTag protein relative to cell nuclei. Next, we characterize the molecular diffusion of the soluble protein, calreticulin, in the context of α 1 -antitrypsin deficiency, which revealed an increase in heterogeneous motion within endoplasmic reticulum inclusions.

Year:

2025

Year:

2024

Volumetric super-resolution microscopy typically encodes the 3D position of single-molecule fluorescence into a 2D image by changing the shape of the point spread function (PSF) as a function of depth. However, the resulting large and complex PSF spatial footprints reduce biological throughput and applicability by requiring lower labeling densities to avoid overlapping fluorescent signals. We quantitatively compare the density dependence of single-molecule light field microscopy (SMLFM) to other 3D PSFs (astigmatism, double helix and tetrapod) showing that SMLFM enables an order-of-magnitude speed improvement compared to the double helix PSF by resolving overlapping emitters through parallax. We demonstrate this optical robustness experimentally with high accuracy ( > 99.2 ± 0.1%, 0.1 locs μm −2 ) and sensitivity ( > 86.6 ± 0.9%, 0.1 locs μm −2 ) through whole-cell (scan-free) imaging and tracking of single membrane proteins in live primary B cells. We also exemplify high-density volumetric imaging (0.15 locs μm −2 ) in dense cytosolic tubulin datasets.

Year:

2024

Parkinson's disease (PD) is a common neurodegenerative condition characterised by the presence in the brain of large intraneuronal aggregates, known as Lewy bodies and Lewy neurites, containing fibrillar α-synuclein. According to the amyloid hypothesis, these large end-stage species form from smaller soluble protein assemblies, often termed oligomers, which are proposed as early drivers of pathogenesis. To date, however, this hypothesis has remained controversial, at least in part because it has not been possible to directly visualise oligomeric aggregates in human brain tissue. Therefore, their presence, abundance and distributions have remained elusive. Here, we present ASA-PD (Advanced Sensing of Aggregates - Parkinson's Disease), an imaging method to generate large-scale α-synuclein oligomer maps in post-mortem human brain tissue. We combined autofluorescence suppression with single-molecule fluorescence methods, which together, enable the detection of nanoscale α-synuclein aggregates. To demonstrate the utility of this platform, we captured ~1.2 million oligomers from the anterior cingulate cortex in human post-mortem brain samples from PD and healthy control patients. Our data revealed a specific subpopulation of nanoscale oligomers that represent an early hallmark of the proteinopathy that underlies PD. We anticipate that quantitative information about oligomer distributions provided by ASA-PD will enable mechanistic studies to reveal the pathological processes caused by α-synuclein aggregation.

Year:

2024

Collaborators (21)

Tuomas Knowles

1920 Professor of Physical Chemistry

University of Cambridge

UNITED KINGDOM
View details

Tammaryn Lashley

University College London

UNITED KINGDOM
View details

Joseph Chambers

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Shriram Venkatesan

Research Specialist

Stowers Institute for Medical Research

UNITED STATES
View details

Mina Ryten

University College London

UNITED KINGDOM
View details

Danny Sahtoe

Hubrecht Institute for Developmental Biology and Stem Cell Research

NETHERLANDS
View details

Michele Vendruscolo

Professor

University of Cambridge

UNITED KINGDOM
View details

Stefan J. Marciniak

Professor of Respiratory Science

University of Cambridge

UNITED KINGDOM
View details

Steven F. Lee

Professor of Biophysical Chemistry

University of Cambridge

UNITED KINGDOM
View details

William A. McEwan

University of Cambridge

UNITED KINGDOM
View details

Georg Meisl

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

David Klenerman

University of Cambridge

UNITED KINGDOM
View details

Alain Goriely

University of Oxford

UNITED KINGDOM
View details

Nicholas Wood

University College London

UNITED KINGDOM
View details

Mathew Horrocks

Full Professor of Biophysics

University of Edinburgh

UNITED KINGDOM
View details

Randal Halfmann

Associate Investigator

Stowers Institute for Medical Research

UNITED STATES
View details

Maria Rodriguez-Lopez

Head of Genomics Facility

Babraham Institute

UNITED KINGDOM
View details

Lucien Weiss

Associate Professor

Polytechnique Montréal

CANADA
View details

David C. Gershlick

University of Cambridge

UNITED KINGDOM
View details

Zane Jaunmuktane

Clinical Lecturer and Honorary Consultant Neuropathologist

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

Sam Daly

PDRA

University of Cambridge

UNITED KINGDOM
View details